TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass (TSBL-OAGB)
TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass: Interim Results of a Randomized Trial
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This is a single-center, prospective, randomized controlled trial comparing two methods for determining biliopancreatic limb length (BPLL) during laparoscopic one-anastomosis gastric bypass (OAGB) in patients with morbid obesity. Eligible patients aged 18-65 years with BMI ≥35 kg/m² (non-Asian) or ≥32.5 kg/m² (Asian populations) who were candidates for primary OAGB were randomized 1:1 using a computer-generated randomization sequence with sequentially numbered, opaque sealed envelopes.
In the intervention (TSBL-based) group, total small bowel length (TSBL) was measured intraoperatively from the ligament of Treitz to the ileocecal valve, and BPLL was calculated as 0.35 × TSBL. In the control (BMI-based) group, BPLL was determined using standard fixed lengths based on BMI category (150 cm, 180 cm, or 200 cm). All other surgical steps were identical between groups.
The primary outcome is percentage excess weight loss (%EWL) assessed longitudinally at baseline, 3, 6, and 12 months. Secondary outcomes include percentage total weight loss (%TWL), BMI, BMI loss, improvement of obesity-related comorbidities, and postoperative complications graded using the Clavien-Dindo classification. Statistical analysis uses linear mixed models to evaluate effects of group, time, and group-by-time interaction.
Because blinding of patients and surgeons was not feasible given the nature of the surgical intervention, outcome assessment relied on objective anthropometric and clinical measures. This record reflects a planned interim analysis conducted on the first 75 of a planned total of 100 enrolled patients, with 51 patients having completed 12-month follow-up at the time of this analysis.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Nurbol Orynbassar
- Numéro de téléphone: +77474528797
- E-mail: nurbolorynbassar@gmail.com
Lieux d'étude
-
-
-
Almaty, Kazakhstan
- Recrutement
- JSC "National Scientific Center of Surgery named after A.N. Syzganov"
-
Contact:
- Nurbol Orynbassar
- Numéro de téléphone: +77474528797
- E-mail: nurbolorynbassar@gmail.com
-
Chercheur principal:
- Adil Shokebaev
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age between 18 and 65 years
- BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
- Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
- Eligibility for primary one-anastomosis gastric bypass (OAGB)
- Provision of written informed consent
Exclusion Criteria:
- BMI below the defined thresholds
- Severe decompensated cardiac, pulmonary, hepatic, or renal disease
- Acute inflammatory conditions
- Active gastric or duodenal ulcer
- Psychiatric disorders or substance abuse
- Pregnancy or breastfeeding
- Active malignancy
- Severe intra-abdominal adhesions due to prior surgery
- Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: TSBL-Based Group
Biliopancreatic limb length (BPL) individualized based on intraoperatively measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL.
|
Biliopancreatic limb length individualized intraoperatively based on measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL, prior to laparoscopic one-anastomosis gastric bypass.
|
|
Comparateur actif: BMI-Based Group
Biliopancreatic limb length (BPL) determined using standard fixed lengths based on BMI category: 150 cm for BMI 35-39.9,
180 cm for BMI 40-49.9,
200 cm for BMI ≥50.
|
Biliopancreatic limb length determined using standard fixed lengths based on preoperative BMI category (150 cm, 180 cm, or 200 cm), prior to laparoscopic one-anastomosis gastric bypass.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Excess Weight Loss (%EWL)
Délai: Baseline, 3 months, 6 months, and 12 months post-surgery
|
EWL defined as the proportion of weight loss relative to excess baseline weight, with ideal body weight defined as BMI 25 kg/m².
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Total Weight Loss (%TWL)
Délai: Baseline, 3 months, 6 months, and 12 months post-surgery
|
TWL assessed as percentage of total body weight loss relative to baseline weight.
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Change
Délai: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Change in body mass index (BMI, kg/m²) from baseline over time.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Loss (BMIL)
Délai: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Reduction in BMI from baseline, expressed as BMI loss (BMIL).
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
Improvement in Obesity-Related Comorbidities
Délai: 12 months post-surgery
|
Change in obesity-related comorbidities, including hypertension and ischemic heart disease, compared between groups.
|
12 months post-surgery
|
|
Postoperative Complications
Délai: 12 months post-surgery
|
Postoperative complications documented and categorized according to the Clavien-Dindo classification system, including anaemia, hair loss, and bowel movement disorder.
|
12 months post-surgery
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- TSBL-BMI-OAGB
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .